Active Recombinant Human CSF1R Protein, GST-tagged

• Cat.No.: CSF1R-1964H
• Product Overview: Human CSF1R (NP_005202.2, 538 a.a. - 972 a.a.) partial recombinant protein with GST tag expressed in Baculovirus infected Sf21 cells.

Specification

• Description: The protein encoded by this gene is the receptor for colony stimulating factor 1, a cytokine which controls the production, differentiation, and function of macrophages. This receptor mediates most if not all of the biological effects of this cytokine. Ligand binding activates the receptor kinase through a process of oligomerization and transphosphorylation. The encoded protein is a tyrosine kinase transmembrane receptor and member of the CSF1/PDGF receptor family of tyrosine-protein kinases. Mutations in this gene have been associated with a predisposition to myeloid malignancy. The first intron of this gene contains a transcriptionally inactive ribosomal protein L7 processed pseudogene oriented in the opposite direction. Alternative splicing results in multiple transcript variants. Expression of a splice variant from an LTR promoter has been found in Hodgkin lymphoma (HL), HL cell lines and anaplastic large cell lymphoma. [provided by RefSeq, Mar 2017]
• Source: Insect Cells
• Species: Human
• Tag: GST
• Form: Liquid
• Bio-activity: The activity was measured by off-chip mobility shift assay. The enzyme was incubated with fluorescence-labeled substrate and Mg (or Mn)/ATP. The phosphorylated and unphosphorylated substrates were separated and detected by LabChip™3000.Substrate : Srctide. ATP: 100 µM.
• Molecular Mass: 76 kDa
• Purity: 77 % by SDS-PAGE/CBB staining.
• Applications: Functional Study
  SDS-PAGE
• Storage: Store at -80 centigrade. Aliquot to avoid repeated freezing and thawing.
• Storage Buffer: In 50 mM Tris-HCl, 150 mM NaCl, pH 7.5 (0.05% Brij35, 1 mM DTT, 10% glycerol)
• Protein length: 538-972

Gene Information

• Gene Name: CSF1R colony stimulating factor 1 receptor [ Homo sapiens ]
• Official Symbol: CSF1R
• Synonyms: CSF1R; colony stimulating factor 1 receptor; FMS, McDonough feline sarcoma viral (v fms) oncogene homolog; macrophage colony-stimulating factor 1 receptor; C FMS; CD115; CSFR; CSF-1-R; CD115 antigen; CSF-1 receptor; FMS proto-oncogene; proto-oncogene c-Fms; macrophage colony stimulating factor I receptor; McDonough feline sarcoma viral (v-fms) oncogene homolog; FMS; FIM2; HDLS; C-FMS; CSF-1R; M-CSF-R
• Gene ID: 1436
• mRNA Refseq: NM_005211
• Protein Refseq: NP_005202
• MIM: 164770
• UniProt ID: P07333

Reviews

01/09/2022

With its remarkable quality, reliability, and the manufacturer's excellent technical support, I am confident that it will be an invaluable asset in driving my scientific inquiries forward and facilitating groundbreaking discoveries in my field.

10/30/2017

This variety allows me to select the most appropriate option based on the specific requirements of my research.

03/10/2017

the manufacturer's commitment to quality control and rigorous testing guarantees the reliability and reproducibility of the CSF1R protein, which is essential for obtaining accurate and consistent results.

Q&As

Are there any FDA-approved drugs targeting CSF1R for clinical use?

Yes, drugs like pexidartinib have been approved for the treatment of certain rare tumors called tenosynovial giant cell tumors (TGCT) that overexpress CSF1R.

How can CSF1R inhibitors impact the tumor microenvironment?

CSF1R inhibitors can modulate the tumor microenvironment by reducing the number of tumor-associated macrophages and promoting an anti-tumor immune response.

Can CSF1R inhibitors be used in combination with other cancer treatments?

Yes, CSF1R inhibitors are often used in combination with chemotherapy and immunotherapy to enhance treatment effectiveness.

What are the potential clinical applications of CSF1R inhibitors?

CSF1R inhibitors are being investigated for cancer therapy to block tumor-promoting macrophages and slow down cancer progression.

Can CSF1R inhibitors be used to treat neurodegenerative diseases?

Research is ongoing, and CSF1R inhibitors are being explored as a potential therapy for neurodegenerative diseases, but no FDA-approved treatments currently exist.